AstraZeneca acquires company with early-stage blood cancer drug candidate

Delaware Business Now

Jul 9, 2022

AstraZeneca agreed to acquire TeneoTwo, Inc., including its clinical-stage CD19/CD3 T-cell engager, TNB-486 blood cancer drug. Anas Younes, senior vice president of Haematology R&D…